Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 2/20 | 0.37 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24689984 | 1.00 | BCAT2 (0.42) | BCAT2MAPK1TDP1NUDT1MEN1 | |
| SCHEMBL30020727 | 0.79 | ALDH1A1 (0.36) | HPGDALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL24690176 | 0.79 | ALDH1A1 (0.36) | HPGDALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL25350701 | 0.78 | MAPK1 (0.53) | BCAT2MAPK1TDP1NUDT1MEN1 | |
| SCHEMBL6502581 | 0.75 | LTA4H (0.49) | CHEK2NPC1RAB9A | |
| SCHEMBL706418 | 0.74 | DHODH (0.45) | CHEK2MAOBNPC1RAB9A | |
| SCHEMBL29151881 | 0.73 | HPGD (0.32) | MAPK1TDP1NUDT1MEN1KMT2A | |
| SCHEMBL24689985 | 0.72 | PTGDR (0.44) | MAPK1MEN1KMT2ACYP1A2CYP2C9 | |
| SCHEMBL14556361 | 0.69 | NOX1 (0.40) | CYP1A2 | |
| SCHEMBL17923129 | 0.68 | BCAT2 (0.49) | BCAT2MAPK1TDP1NUDT1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240254093-A1 | GPR35 Agonist Compounds | NXERA PHARMA UK LIMITED (GB) | 2024-08-01 | — | — | US | disclosed |
| EP-4326708-A1 | GPR35 AGONIST COMPOUNDS | Heptares Therapeutics Limited (GB) | 2024-02-28 | — | — | EP | disclosed |
| WO-2022224212-A1 | GPR35 AGONIST COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2022-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254093-A1 | GPR35 Agonist Compounds | GPR35, GPR119, GPR68 | BCAT2 2302/4885MAPK1 1217/4885TDP1 3138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.